Wegovy Explained: Effects, Side Effects, and Price, All in One Place

What Is Wegovy: How the GLP-1 Analog Works

Wegovy is an obesity treatment developed by the Danish pharmaceutical company Novo Nordisk, with semaglutide as its active ingredient. Interestingly, this is the same active ingredient found in Ozempic, the well-known type 2 diabetes medication. The two products differ in their approved indication and maximum dose, but they belong to the same drug class. Ozempic was approved for blood sugar control in type 2 diabetes, while Wegovy went through a separate clinical program specifically for chronic weight management.

Semaglutide is a "GLP-1 receptor agonist" — a compound engineered to mimic GLP-1 (glucagon-like peptide-1), a hormone your gut naturally releases after eating. This hormone acts through three main pathways:

• Glucose-dependent insulin release: It boosts insulin secretion only when blood sugar is elevated, lowering the risk of hypoglycemia.
• Slower gastric emptying: Food stays in the stomach longer, extending the feeling of fullness.
• Appetite regulation in the brain: It acts on the hypothalamus, reportedly reducing appetite and food cravings themselves.

Wegovy comes as a pre-filled injector pen, self-administered once a week into the abdomen, thigh, or upper arm. Starting at a high dose right away tends to cause severe digestive side effects, so the standard approach is a gradual titration schedule: 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg over roughly 16 to 20 weeks. In Korea, the Ministry of Food and Drug Safety approved Wegovy in April 2023, and actual prescriptions and sales began on October 15, 2024.

Why a Once-Weekly Injection?

Semaglutide is a chemically modified version of the body's naturally occurring GLP-1 hormone, engineered to break down far more slowly. Natural GLP-1 has a half-life of only a few minutes in the bloodstream, but semaglutide's fatty acid side chain binds to albumin, extending its half-life to roughly seven days. That's what makes a once-weekly injection enough to maintain a steady blood concentration — a meaningful convenience upgrade over earlier-generation obesity drugs like Saxenda (liraglutide), which required daily injections.

Wegovy vs. Ozempic: What's the Difference?

Both products contain semaglutide as the active ingredient, but Ozempic was developed for blood sugar control in type 2 diabetes and is capped at a lower maximum dose (up to 2.0mg, varying by country), while Wegovy went through its own clinical trials specifically for weight management and was approved for use up to 2.4mg. In short, think of Wegovy as "the same molecule, redesigned and dosed higher for the specific purpose of weight loss." In some countries, off-label use of Ozempic for weight loss by people without diabetes has stirred social controversy — in Korea, this kind of off-indication prescribing is strictly restricted.

Globally, Wegovy's rollout started with FDA approval in 2021, followed by Europe, then Japan (February 2024, the first launch in Asia), and eventually Korea — the second country in Asia and the tenth worldwide — where prescriptions began on October 15, 2024.

What the Clinical Trials Show About Weight Loss

Wegovy's approval was built on the STEP (Semaglutide Treatment Effect in People with Obesity) trial program, run by Novo Nordisk. Each trial tested semaglutide's efficacy and safety under different conditions.

Keep in mind these figures come from tightly controlled clinical trial conditions, alongside monthly lifestyle counseling — they're averages, not guarantees. In everyday clinical practice, side effects often delay dose escalation or lead to discontinuation partway through, so real-world weight loss tends to run somewhat lower, around 8–12% on average. Results also vary significantly based on individual metabolism, diet, and whether exercise is part of the routine.

Beyond weight loss, at the Korean launch symposium, clinical data was presented showing a reduced risk of major cardiovascular events — cardiovascular death, non-fatal heart attack, and non-fatal stroke. Metabolic markers like blood pressure, fasting glucose, and cholesterol also tended to improve alongside weight loss.

The SELECT Trial: Looking at Cardiovascular Risk

The most notable follow-up study related to Wegovy is the SELECT cardiovascular outcomes trial. Conducted across 41 countries in 17,604 people who had established cardiovascular disease and were overweight or obese but did not have diabetes, the trial found that participants on semaglutide 2.4mg had a 20% lower rate of major adverse cardiovascular events (MACE) — a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke — compared with placebo. In absolute terms, the event rate dropped from 8.0% in the placebo group to 6.5% in the treatment group. However, permanent discontinuation due to gastrointestinal side effects was roughly twice as high in the treatment group (16.6% vs. 8.2% for placebo), underscoring that benefits and side effects need to be weighed together.

A follow-up analysis of the SELECT trial also found a favorable signal for kidney-related outcomes: a composite measure of kidney disease progression occurred in 1.8% of the treatment group versus 2.2% in the placebo group. That said, these secondary findings still require further confirmation, and it's worth being clear that Wegovy is not approved as a treatment for kidney disease.

In a head-to-head comparison with another GLP-1 drug (STEP 8), semaglutide 2.4mg produced an average 68-week weight loss of 15.8%, clearly higher than liraglutide's (Saxenda) 6.4% over the same period. That said, the two drugs differ in half-life and dosing schedule (once weekly vs. daily), so direct comparisons should be read with some caution.

Weight Loss Plateaus: Is That Normal?

Many people using Wegovy eventually hit a point where the scale simply stops moving. In the STEP 1 trial, weight loss also began to flatten out and stabilize around week 60. This isn't a sign the drug has stopped working — it's the body's natural adaptive response, since basal metabolic rate tends to drop as weight decreases and the body settles into its new equilibrium. Rather than rushing to increase the dose on your own during this phase, it's better to review activity levels or the quality of your diet and plan next steps together with your physician.

Side Effects and Precautions You Should Know

Because semaglutide acts directly on gastrointestinal motility, digestive side effects are by far the most common issue. Symptoms tend to be most noticeable during the dose-escalation phase.

Easing Digestive Side Effects

Nausea and indigestion are near-universal experiences for Wegovy users at some point, but a few lifestyle adjustments can meaningfully reduce how intense they feel.

• Eat smaller, more frequent meals: Smaller portions put less strain on the stomach than large ones.
• Avoid fatty or heavily spiced food: With gastric emptying already slowed, greasy meals tend to worsen bloating and nausea.
• Eat slowly and chew thoroughly: Eating too fast widens the gap between your fullness signal and actual intake, which can worsen discomfort.
• Stay well hydrated: Helps prevent constipation and supports overall comfort.
• Avoid lying down right after eating: Staying upright and lightly active after meals is reported to ease digestive discomfort.

If symptoms persist or interfere with daily life despite these steps, don't adjust the dose on your own — talk to your prescribing physician about slowing the titration schedule.

Taking Other Medications?

Because Wegovy slows gastric emptying, it can also affect how quickly oral medications are absorbed. If you're taking a blood thinner like warfarin, more frequent monitoring of clotting levels is recommended early in treatment, and if you're on oral contraceptives, it's worth discussing potential absorption delays with your doctor. Combining Wegovy with insulin or sulfonylurea-class diabetes medications raises the risk of hypoglycemia, so prescribing physicians often adjust the dose of those existing medications accordingly. The safest approach is to disclose every medication and supplement you're taking at each visit.

Separately, the possible link between GLP-1 drugs and suicidal thoughts or behavior has been under joint investigation by the US FDA and the European EMA since 2023. Some signals emerged from analyses of WHO adverse-event databases, keeping the debate alive, but in early 2026 the FDA concluded, after safety review, that "the evidence does not support an increased risk of suicidal ideation or behavior," and ordered the related warning language removed from product labels. Still, if you're taking antidepressants or tend to be sensitive to mood changes, it's wise to monitor your mental state during treatment and report any concerning changes to your doctor right away.

Dosing, Prescriptions, and Pricing in Korea

Who Can Get a Prescription

Wegovy isn't available simply because someone wants it. In general, candidates are adults with a body mass index (BMI) of 30 or higher (obesity), or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, dyslipidemia, or type 2 diabetes (overweight with comorbidity). Purely cosmetic use for a modest weight goal doesn't meet the approved criteria — a physician determines eligibility based on BMI and comorbidities during the consultation.

It's also worth noting that Wegovy's global trials used Western BMI cutoffs, while obesity care in Korea often references the Korean Society for the Study of Obesity's own criteria for Asian populations (BMI 25 or higher classified as obesity), since multiple studies have found that Asian individuals tend to have higher body fat percentage and metabolic disease risk than Western individuals at the same BMI. So eligibility isn't decided by a single number alone — physicians typically weigh body composition and blood test results together.

Pre-Treatment Checklist

If you're considering a Wegovy prescription, having the following ready before your appointment can make the consultation go much more smoothly.

• Your recent weight history and any weight management methods you've already tried
• Personal or family history of thyroid disease, pancreatitis, gallbladder disease, or kidney disease
• A full list of every prescription medication, supplement, and health product you currently take
• Whether you're pregnant or planning pregnancy (use isn't recommended if either applies)
• Any existing digestive conditions, such as acid reflux or irritable bowel syndrome

Wegovy uses a stepwise "titration" schedule to minimize side effects. The standard escalation looks like this:

After being prescribed by a doctor, you can pick up the medication at a pharmacy and self-inject at home, or visit a clinic weekly to receive the injection there. A physician's prescription is legally required for self-injection use, and selling the drug without a prescription is illegal in Korea.

Storage and Self-Injection Tips

Unopened Wegovy pens should be refrigerated (2–8°C), though they can be kept at room temperature (up to 30°C) for up to 28 days if needed. Injection sites — the abdomen, thigh, or upper arm — should be rotated weekly, since repeatedly injecting the same spot can lead to lipodystrophy, a hardening of the tissue under the skin. As long as you inject on the same day each week, the specific time of day doesn't need to be fixed. If you miss a dose by a day or two, take it as soon as possible; if fewer than two days remain until your next scheduled dose, it's generally recommended to simply wait for the next one. For the most accurate guidance, always follow the instructions from your prescribing clinic.

Pricing has shifted over time. At Korea's October 2024 launch, the wholesale price for a 4-week supply was about 372,000 KRW, but as global demand surged and supply grew tight, it climbed above 400,000 KRW by February 2025. After the competing drug Mounjaro (tirzepatide) launched in Korea in August 2025, Novo Nordisk cut supply prices by up to 42% at the lower-dose tiers and introduced dose-tiered pricing. As a result, the monthly cost for patients just starting on low doses dropped considerably, while the 2.4mg maintenance dose has seen comparatively little price change.

Wegovy is a non-reimbursed prescription drug under Korea's national health insurance, meaning clinic consultation fees and pharmacy prices are set independently by each provider. As a result, out-of-pocket costs for the same dose can vary meaningfully between clinics and pharmacies, so it's worth comparing prices at a few places before starting treatment.

How Korea Compares Globally

At the same 2.4mg dose, prices vary substantially by country depending on insurance systems and market conditions. Converting local currency prices to a rough KRW equivalent gives a general sense of scale — though these figures fluctuate with exchange rates and local policy changes, so treat them as reference points only.

One thing to keep in mind is how you can access a prescription. Due to concerns about misuse, telehealth prescriptions for GLP-1 obesity drugs, including Wegovy, have been restricted in Korea since December 2, 2024. That means an online consultation alone is no longer enough — an in-person visit and physical examination are required. Once prescribed, you can either purchase the medication at a pharmacy and self-inject at home, or visit the clinic weekly for the injection.

Is It Approved for Teens? A 2025 Indication Expansion

In October 2025, Korea's Ministry of Food and Drug Safety expanded Wegovy's approved indication to include adolescents aged 12 to under 18 who are obese or overweight with at least one weight-related comorbidity. The decision was based on the "STEP TEENS" phase 3 trial, a 68-week study of 201 adolescents. In that trial, participants on Wegovy 2.4mg saw their BMI drop by an average of 16.1%, while the placebo group's BMI actually increased by 0.6%. In terms of body weight, the treatment group lost an average of 15.3kg compared with a 2.4kg gain in the placebo group. The share of participants who achieved at least 5% weight loss was also markedly higher in the treatment group (72.5%) than in the placebo group (17.7%), and over the 68-week observation period, no effects on growth markers or pubertal development were identified.

According to Korea's Disease Control and Prevention Agency, the obesity rate among middle and high school students rose from 7.5% in 2015 to 12.5% in 2024 — roughly a 1.7-fold increase over a decade — underscoring the growing importance of managing adolescent obesity. That said, alongside the expanded approval, regulators have emphasized cautious prescribing and misuse-prevention measures, stressing that the expansion should not "lead to prescriptions for adolescents who are already very thin, or to indiscriminate use." Whether to prescribe for a teenager should be carefully determined through evaluation by a pediatric or pediatric endocrinology specialist.

Why Food Thoughts Seem to Quiet Down: The "Food Noise" Effect

One experience Wegovy users commonly report is that "thoughts about food itself just seem to fade." This is increasingly described using the term "food noise" — the recurring thoughts or cravings that pop up around specific foods. GLP-1 receptors aren't limited to the digestive system; they're also found in brain regions associated with reward and craving, which may explain why semaglutide seems to reduce not just physical hunger, but the mental preoccupation with food itself.

Many users experience this as a welcome change, but some also find it uncomfortable to lose interest or enjoyment in food altogether. There have also been reports of appetite suppression going far enough to compromise adequate nutrient intake, so it's worth making a deliberate effort to structure meals around sufficient protein and micronutrients while on treatment.

Watch Out for Counterfeit Wegovy

Given the global shortage and sky-high demand, concerns have grown around counterfeit or illegally distributed Wegovy sold through social media, overseas resellers, or secondhand marketplaces outside official channels. Products with incorrect ingredients or inaccurate dosing can lead to unexpected side effects or even infection risk. Wegovy should always be obtained with a physician's prescription through a licensed pharmacy — avoid any channel that sells without a prescription or advertises suspiciously low prices.

Wegovy vs. Mounjaro vs. Saxenda

Korea's obesity treatment market includes several options beyond Wegovy. Here's a quick comparison of their ingredients and characteristics.

Mounjaro is a "dual agonist" that acts on both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, and some studies have reported higher average weight loss than Wegovy, making it the driver of Korea's recent price competition. Saxenda, an earlier first-generation GLP-1 drug, produces comparatively less weight loss but has a longer track record and a richer body of safety data from years of real-world use. Which drug is right for you depends on your weight, comorbidities, budget, and tolerance for side effects — a decision best made together with a specialist.

For those uncomfortable with injections, an oral version of semaglutide called Rybelsus also exists. However, it's currently approved as a diabetes treatment in most countries, including Korea, and a higher-dose oral formulation for weight loss (Rybelsus 25mg) is separately approved only in a handful of countries. Oral absorption is also lower than injection, which is why a higher dose is needed to achieve a comparable effect.

Managing Rebound Weight Gain and Muscle Loss After Stopping

The most practical question surrounding Wegovy is whether you have to stay on it forever. A meta-analysis by Oxford University researchers, published in the BMJ, found that after stopping obesity medications, weight climbs back by an average of 0.4kg per month — roughly four times faster than the rate of regain after stopping a diet-and-exercise-based weight loss program (0.1kg per month). Weight returned to pre-treatment levels in an average of 1.7 years after stopping medication, compared with an average of 3.9 years after discontinuing a lifestyle-based program. Another large-scale meta-analysis found that about 75% of lost weight returns within 12 months of stopping, with only around 25% maintained long-term.

Muscle loss is another frequently raised concern. Because Wegovy strongly suppresses appetite and reduces overall calorie intake, several observational studies have pointed out that fat isn't the only thing lost — muscle mass can decline too. Less muscle mass means a lower basal metabolic rate, which can make it easier for weight to creep back once the medication is stopped, creating something of a vicious cycle.

In the end, Wegovy is best understood as a "supporting tool" that adjusts appetite and metabolism for a defined period. If the extra breathing room it creates isn't used to actually change eating and exercise habits, weight and metabolic markers are likely to drift back toward baseline once treatment stops.

How Long Should You Stay on It?

As the clinical field increasingly treats obesity as a chronic condition, Wegovy is often approached the way blood pressure or diabetes medications are — as long-term or intermittent "maintenance treatment" as needed. The STEP 5 trial was specifically designed to test whether weight loss holds up over 104 weeks (2 years), and it found that the reduction remained stable without a major decline. On the flip side, as discussed above, weight tends to return relatively quickly after stopping — which suggests it's more realistic to think of Wegovy as part of a long-term weight management plan from the outset, rather than a short-term fix.

If cost or side effects make long-term use difficult, options like maintaining a lower dose after reaching your target weight, or adjusting to a biweekly schedule, can be discussed with your physician. Any such adjustment should always be made under a specialist's guidance — extending the dosing interval on your own is not recommended.

Frequently Asked Questions

Q. Can I skip diet and exercise if I'm on Wegovy?
A. Even in the clinical trials, participants received monthly lifestyle counseling alongside the medication. While the drug suppresses appetite, pairing it with a balanced diet and consistent activity tends to lead to more stable results and better muscle preservation.

Q. Can I just stop once I hit my target weight?
A. Stopping abruptly is likely to lead to fairly quick weight regain. As noted earlier, some research shows weight can return to baseline in as little as 1.7 years after stopping, so it's recommended to taper the dose gradually or plan a maintenance strategy with your doctor.

Q. Can I get a prescription without diabetes?
A. Yes — Wegovy is approved as an obesity treatment for overweight adults with weight-related comorbidities, regardless of diabetes status. That said, the exact eligibility criteria are determined by a physician during consultation.

Q. What if the side effects are too severe?
A. If you experience severe abdominal pain, persistent vomiting, or jaundice, stop taking the medication and see a doctor immediately. For milder nausea or indigestion, your prescribing physician can often help by slowing the dose escalation or reverting to a previous dose.

Q. Can I get a Wegovy prescription through telehealth?
A. Since December 2024, telehealth prescriptions for obesity medications, including Wegovy, have been restricted in Korea. An in-person visit and physical exam are required to get a prescription.

Q. Is Wegovy or Mounjaro better?
A. Some clinical data suggests slightly higher average weight loss with Mounjaro, but large-scale head-to-head data specific to Korean patients is still limited. Side effect profiles, comorbidities, and cost should all be weighed together with your physician to make the safest choice.

Conclusion: Is Wegovy Right for You?

Wegovy has demonstrated clinically validated weight-loss effects along with potential cardiovascular benefits — but the idea that "you'll lose weight and keep it off just by taking this" doesn't reflect reality. There's a lot to consider, from digestive side effects to thyroid- and pancreas-related contraindications, and a separate plan is needed to manage weight and muscle mass after stopping.

Above all, remember that averages from clinical trials and any one person's actual experience can differ. Some people see strong results with fewer side effects than expected, while others find dose escalation difficult due to gastrointestinal issues. Treating obesity isn't something a single medication resolves on its own — it's a process that requires looking comprehensively at your health status, lifestyle, budget, and long-term maintenance plan. If you're considering treatment, it's worth having a thorough conversation with an obesity medicine or family medicine specialist before deciding whether it's the right fit for you.